Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The PARP inhibitor Lynparza slows disease progression in women with BRCA-related ovarian cancer.
The drug, a PARP inhibitor, blocks proteins that help repair damaged DNA, and so can cause tumor cells that carry a BRCA mutation to die.
In tumors with missing or mutated BRCA genes, PARP inhibitors plus other drugs have worked well—but the cancer often becomes drug-resistant.
New study finds that simple cysts should be considered normal and ignored.
Physicians recognize that ovarian cancer isn’t a single disease but a group of related disorders with distinct genetic and cellular features
PARP inhibitor demonstrates unprecedented improvement in progression-free survival.
Other pain relievers might raise the odds, however.
September is Ovarian Cancer Awareness Month
The search continues for new biomarkers, better outcomes and, yes, cures for this deadly disease.
Genetic mutation raises the risk of breast, ovarian and prostate cancers.
Talking with other people who’ve shared your experience with breast cancer can make all the difference in the world.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.